Key Insights

Highlights

Success Rate

86% trial completion

Published Results

12 trials with published results (18%)

Research Maturity

51 completed trials (77% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

12.1%

8 terminated out of 66 trials

Success Rate

86.4%

-0.1% vs benchmark

Late-Stage Pipeline

41%

27 trials in Phase 3/4

Results Transparency

24%

12 of 51 completed with results

Key Signals

12 with results86% success

Data Visualizations

Phase Distribution

50Total
Not Applicable (6)
Early P 1 (1)
P 1 (6)
P 2 (10)
P 3 (18)
P 4 (9)

Trial Status

Completed51
Terminated8
Unknown4
Enrolling By Invitation1
Withdrawn1
Recruiting1

Trial Success Rate

86.4%

Benchmark: 86.5%

Based on 51 completed trials

Clinical Trials (66)

Showing 20 of 20 trials
NCT03828773Not ApplicableRecruitingPrimary

PTX3-targeted Antifungal Prophylaxis

NCT01322698CompletedPrimary

Staging Candidiasis in ICU Patients

NCT02145832Phase 2CompletedPrimary

Fluconazole Versus Micafungin in Neonates With Candidiasis

NCT06472765Enrolling By Invitation

Vaginal Ecosystem and Network in the United States Study

NCT05707156Completed

Prospective Observational Study on the Incidence of Opportunistic Fungal Infections

NCT01982071Phase 4Terminated

A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia

NCT02646800Phase 4Terminated

Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp

NCT05235711Completed

The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis

NCT00304772Phase 4WithdrawnPrimary

Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients

NCT05044156Completed

Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women

NCT00000744Not ApplicableCompletedPrimary

A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women

NCT00000788Phase 1CompletedPrimary

A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone

NCT00000676Phase 3CompletedPrimary

Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)

NCT04122560Phase 4Completed

Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration

NCT02666716CompletedPrimary

Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients

NCT04502277Early Phase 1UnknownPrimary

Bioavailability of Flucanazole

NCT01447407Phase 1Completed

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

NCT02860845Phase 4CompletedPrimary

Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections

NCT00109525Completed

Early Diagnosis of Candidiasis in Premature Infants

NCT00734539Phase 3CompletedPrimary

Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight

Scroll to load more

Research Network

Activity Timeline